Search results
Results From The WOW.Com Content Network
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin bladder cancer: GDP gemcitabine, dexamethasone, cisplatin: Non-Hodgkin lymphomas and Hodgkin lymphoma: GemOx or GEMOX: gemcitabine, oxaliplatin: Non-Hodgkin lymphomas: GVD: gemcitabine, vinorelbine, pegylated liposomal doxorubicin: Hodgkin lymphoma: GemOx-R or GEMOX-R or R-GemOx ...
Gemcitabine is a chemotherapy drug that works by killing any cells that are dividing. [11] Cancer cells divide rapidly and so are targeted at higher rates by gemcitabine, but many essential cells also divide rapidly, including cells in skin, the scalp, the stomach lining, and bone marrow, resulting in adverse effects. [17]: 265
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
%PDF-1.4 %âãÏÓ 369 0 obj > endobj xref 369 46 0000000016 00000 n 0000001804 00000 n 0000002125 00000 n 0000002471 00000 n 0000002653 00000 n 0000002822 00000 n 0000003082 00000 n 0000003523 00000 n 0000004118 00000 n 0000004303 00000 n 0000004995 00000 n 0000005139 00000 n 0000005166 00000 n 0000005629 00000 n 0000006590 00000 n 0000007559 ...
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. [37] [38] They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. [41] Non-classical alkylating agents include procarbazine and hexamethylmelamine. [37] [38]
Gemcitabine progresses through a similar mechanism, causing cells in the S-phase to disrepair DNA damage caused by the radiation. Platinum analogs such as cisplatin inhibit DNA repair by cross linking strands, and so aggravate the effects of DNA damage induced by radiation. [ 1 ]
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...